Pancreas Neoplasms
21
3
3
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.5%
2 terminated out of 21 trials
81.8%
-4.7% vs benchmark
0%
0 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (21)
Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.
PROMs After Pancreatectomy
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure
Robotic vs Open Pancreatoduodenectomy
Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Epidural Analgesia Use in Pancreatic Resections
Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion
Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer